Acquisition Pending
AbbVie acquisition of Apogee Therapeutics
US$11bn equity value
Announced 22 Jun 2026 · NASDAQ: APGE · US$135.11 cash per share
Advisers
Apogee Therapeutics
Target
- Financial adviser
- Legal adviser
- Fairness opinion
- Target
- Apogee Therapeutics
- Acquirer
- AbbVie
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Dermatology, Drug Development
In the league tables
Similar deals
- GSK acquisition of Nuvalent Jun 2026 · US$11bn · Biotech
- Novartis acquisition of Avidity Biosciences Oct 2025 · US$11bn · Biotech
- Merck & Co. acquisition of Terns Pharmaceuticals Mar 2026 · US$6.7bn · Biotech
- Eli Lilly and Company acquisition of AttaiBeckley 2026 · US$3.8bn · Biotech
- Gilead Sciences acquisition of Tubulis Apr 2026 · US$3.1bn · Biotech
Sources
- Jun 2026 Kirkland Advises Apogee Therapeutics on $10.9 Billion Sale to Abbvie kirkland.com
- Jun 2026 Jefferies: Financial Advisor: Sale to AbbVie jefferies.com
- 22 Jun 2026 Press release (EX-99.1, exhibit), to Acquire Apogee Therapeutics, Deepening Immunology Portfolio sec.gov
- 22 Jun 2026 Press release (EX-99.1, exhibit), AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio sec.gov
- 22 Jun 2026 AbbVie to Acquire Apogee Therapeutics paulweiss.com
- 22 Jun 2026 Press release (PR Newswire), AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio prnewswire.com
- 13 Jul 2026 Definitive merger proxy statement (DEFM14A), Apogee Therapeutics, Inc. sec.gov




